Jason Weirather

17PUBLICATIONS
162CO-AUTHORS
Innate immunityMedical molecular engineering of nucleic acids and proteinsMolecular targetsTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Sep 04, 2025
Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8+ and PD-1+ Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors.

Joao V Alessi, James R Lindsay, Anita Giobbie-Hurder

|Apr 11, 2025
First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell-Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma.

F Stephen Hodi, Anita Giobbie-Hurder, Kwasi Adu-Berchie

|Dec 13, 2024
Next-Generation Sequencing-Based MSI Scoring Predicts Benefit in Mismatch Repair-Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D.

Jonathan D Schoenfeld, Nilofer S Azad, Jacob Gross

|Jan 18, 2024
Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates.

Candace L Haddox, Michael J Nathenson, Emanuele Mazzola

|Jan 11, 2024
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer.

Biagio Ricciuti, Giuseppe Lamberti, Sreekar R Puchala

|Sep 20, 2023
EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade.

Saba Tabasum, Dinesh Thapa, Anita Giobbie-Hurder

Pageof 3

Frequent Collaborators

5 joint publications

Scott J Rodig

5 joint publications

Anita Giobbie-Hurder

4 joint publications

F Stephen Hodi

4 joint publications

Kathleen Pfaff